La Luna, nuestro satélite natural, ha sido un objeto de fascinación y misterio a lo largo de la historia humana. Pero ¿alguna vez te has preguntado qué sucedería si la Luna se liberara de la atracción gravitatoria de la Tierra y fuera arrojada al espacio ext …
El escenario apocalíptico: ¿Qué ocurriría si la Luna escapara de la gravedad terrestre? Read More »
SNIPR Biome ApS announces positive interim clinical results from its Phase 1 clinical trial with SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.
Cambrex celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.
AbbVie announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active systemic lupus erythematosus who continued to receive standard lupus therapies.
THINK Surgical, Inc. recently announced that its TMINI™ Miniature Robotic System has received 510 clearance from the U.S. Food and Drug Administration.
La energía solar fotovoltaica ha experimentado un crecimiento exponencial en las últimas décadas, convirtiéndose en una de las principales fuentes de energía renovable en todo el mundo. Con su capacidad para generar electricidad limpia y abundante a partir de la ra …
Energía Solar Fotovoltaica y Paneles Solares: La revolución energética sostenible Read More »
ValnevaSE, a specialty vaccine company, announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon.
Valneva Announces the Availability of Documentation for its Shareholder Meeting Read More »
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that members of management will participate in two upcoming investor conferences in June.
argenx to Present at Upcoming June 2023 Investor Conferences Read More »
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis.
Ascentage Pharma announced that the Center for Drug Evaluation of China National Medical Products Administration has recommended olverembatinib, Ascentage Pharma’s lead novel drug candidate, for a Breakthrough Therapy Designation for the treatment of patients with succinate dehydrogenase -deficient gastrointestinal stromal tumor who had received first-line treatment.
